Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882.

Dingemanse J, Nicolas LB, van Bortel L.

Eur J Clin Pharmacol. 2014 Jun;70(6):675-84. doi: 10.1007/s00228-014-1674-1.

PMID:
24728182
2.

Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.

Hoch M, Hoever P, Theodor R, Dingemanse J.

Eur J Clin Pharmacol. 2013 Jun;69(6):1235-45. doi: 10.1007/s00228-012-1470-8.

PMID:
23334403
3.

Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.

Teng R, Mitchell PD, Butler KA.

Eur J Clin Pharmacol. 2013 Mar;69(3):477-87. doi: 10.1007/s00228-012-1369-4.

PMID:
22922682
4.

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.

Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM.

Antimicrob Agents Chemother. 2001 Dec;45(12):3445-50.

5.

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.

Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P.

Clin Pharmacol Ther. 2000 Oct;68(4):391-400.

PMID:
11061579
7.

Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.

Piscitelli S, Kim J, Gould E, Lou Y, White S, de Serres M, Johnson M, Zhou XJ, Pietropaolo K, Mayers D.

Br J Clin Pharmacol. 2012 Aug;74(2):336-45. doi: 10.1111/j.1365-2125.2012.04194.x.

8.

Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.

Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y, Aberg JA; AIDS Clinical Trials Group A5108 Team..

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):307-12.

PMID:
15980690
9.

Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH.

Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):75-81. doi: 10.1002/pds.1866.

PMID:
19802823
10.

Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.

Shin J, Pauly DF, Pacanowski MA, Langaee T, Frye RF, Johnson JA.

Pharmacotherapy. 2011 Oct;31(10):942-50. doi: 10.1592/phco.31.10.942.

11.

Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin.

Lilja JJ, Kivistö KT, Neuvonen PJ.

Clin Pharmacol Ther. 2000 Oct;68(4):384-90.

PMID:
11061578
12.

Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.

Molden E, Skovlund E, Braathen P.

Drug Saf. 2008;31(7):587-96.

PMID:
18558792
13.

Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.

Hulskotte EG, Feng HP, Xuan F, Gupta S, van Zutven MG, O'Mara E, Wagner JA, Butterton JR.

Antimicrob Agents Chemother. 2013 Jun;57(6):2582-8. doi: 10.1128/AAC.02347-12.

14.

Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects.

DeGorter MK, Urquhart BL, Gradhand U, Tirona RG, Kim RB.

J Clin Pharmacol. 2012 Nov;52(11):1689-97. doi: 10.1177/0091270011422815.

PMID:
22167570
15.

Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.

Hoch M, Hoever P, Alessi F, Theodor R, Dingemanse J.

Eur J Clin Pharmacol. 2013 Mar;69(3):523-32. doi: 10.1007/s00228-012-1403-6.

PMID:
22990330
16.

Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.

Polli JW, Hussey E, Bush M, Generaux G, Smith G, Collins D, McMullen S, Turner N, Nunez DJ.

Xenobiotica. 2013 Jun;43(6):498-508. doi: 10.3109/00498254.2012.739719.

PMID:
23256625
17.

Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.

Bakhai A, Rigney U, Hollis S, Emmas C.

Pharmacoepidemiol Drug Saf. 2012 May;21(5):485-93. doi: 10.1002/pds.2308.

PMID:
22237927
18.

Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.

Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP.

J Clin Pharmacol. 2008 Nov;48(11):1323-38. doi: 10.1177/0091270008323258.

PMID:
18784280
19.

Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.

Kokudai M, Inui N, Takeuchi K, Sakaeda T, Kagawa Y, Watanabe H.

J Clin Pharmacol. 2009 May;49(5):568-73. doi: 10.1177/0091270009332435.

PMID:
19398603
20.

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

Neuvonen PJ, Kantola T, Kivistö KT.

Clin Pharmacol Ther. 1998 Mar;63(3):332-41.

PMID:
9542477

Supplemental Content

Support Center